Featured Research

from universities, journals, and other organizations

Greater R&D funding needed to fight diseases affecting world's poor, experts say

Date:
June 21, 2011
Source:
Sabin Vaccine Institute
Summary:
Despite significant advancements in increasing distribution and development of vaccines against childhood killer diseases -- including pneumococcal disease, rotavirus, and Haemophilus influenzae type B -- global efforts to reduce the burden of infection from neglected tropical diseases have greatly lagged, argue experts.

Despite significant advancements in increasing distribution and development of vaccines against childhood killer diseases -- including pneumococcal disease, rotavirus, and Haemophilus influenzae Type B -- global efforts to reduce the burden of infection from neglected tropical diseases (NTDs) have greatly lagged, argues Sabin Vaccine Institute (Sabin) President Dr. Peter Hotez in an article for the June edition of Health Affairs.

Related Articles


NTDs, a group of 17 parasitic infections, represent a significant contributor to global poverty, and have well documented chronic and disabling effects. Yet efforts to develop vaccines for NTDs have not benefitted from larger ongoing initiatives to combat major childhood diseases.

In his article, "A Handful of 'Antipoverty' Vaccines Exist for Neglected Diseases, But the World's Poorest Billion People Need More," Dr. Hotez cites three critical reasons for the lack of interest in "antipoverty" vaccines:

  • Though NTDs disable, they do not typically cause high levels of mortality leading some in the public health community to misleadingly conclude that NTDs are not a significant public health threat;
  • NTDs predominately occur in rural settings and are largely hidden diseases unknown to the public and infrequently documented; and,
  • Pharmaceutical companies are reluctant to make an investment in NTD vaccines because there is no financial incentive.

Public-private partnerships increasingly represent an innovative mechanism for developing NTD vaccines, states Dr. Hotez in his article. In particular, manufacturers from middle-income countries are increasingly partnering with U.S. organizations and academic institutions to generate a pipeline of vaccines for NTDs. Sabin's vaccine development program -- currently developing vaccines for human hookworm infection and schistosomiasis -- represents one of a limited number of such partnerships.

Dr. Hotez concludes by stating that "developing a new generation of antipoverty vaccines represents a highly innovative and meaningful approach to eliminating the world's neglected diseases, lifting the bottom billion out of poverty, and promoting international diplomacy."

To expand its own vaccine development efforts, Sabin recently announced a new partnership with Texas Children's Hospital and Baylor College of Medicine (BCM) to build a new center in Houston dedicated to developing vaccines for diseases of poverty. Sabin will transfer its vaccine operations to new laboratories at Texas Children's Hospital in September and will continue working with existing and new partners.


Story Source:

The above story is based on materials provided by Sabin Vaccine Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. P. Hotez. A Handful Of 'Antipoverty' Vaccines Exist For Neglected Diseases, But The World's Poorest Billion People Need More. Health Affairs, 2011; 30 (6): 1080 DOI: 10.1377/hlthaff.2011.0317

Cite This Page:

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins